Require 503A compounders to report to the FDA any out-of-state shipments of compounded drugs containing approved active ingredients above a prescription threshold.
I will require 503A drug compounders to report to the FDA any out-of-state shipments of compounded drugs containing approved active ingredients above a prescription threshold.
Occurrences
Evidence
The Senate office’s legislation page lists S.3794, the SAFE Drugs Act of 2026, with latest action: 'Read twice and referred to the Committee on Health, Education, Labor, and Pensions.'
Banks said he introduced the SAFE Drugs Act, and the listed key provisions include: 'Require 503A compounders to report to the FDA any out-of-state shipments of compounded drugs containing approved active ingredients above a prescription threshold.'
Assessments
Banks introduced S.3794, the SAFE Drugs Act of 2026, which directly included the promised requirement for 503A compounders to report qualifying out-of-state shipments to FDA. However, current official bill status shows the measure only reached introduction and referral to the Senate HELP Committee on February 5, 2026, with no enactment or implementation. This is a serious same-term legislative attempt, but the promised federal requirement has not been delivered.